# Pronota NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pronota

- Industry: Biotechnology
- Headquarters: Belgium
- Website: www.pronota.com
- Total disclosed funding: $29M
- Latest round: Series C (Dec 19, 2012)
- Investors on record: 9

## About

Pronota NV is a Belgium-based company focused on domain brokerage, facilitating the acquisition of premium internet domain names for businesses and individuals, enhancing their online presence and brand visibility.Pronota NV is a domain brokerage company that specializes in the sale of premium internet domain names. The company was founded in Belgium and has undergone significant funding rounds, including a Series C round in January 2012, raising EUR 3.7 million from various investors including EQT Life Sciences, Gimv, and Johnson & Johnson Innovation. The founder's history remains undisclosed, but the company has established itself firmly in the domain brokerage sector.Pronota.com operates within the domain brokerage sector, specializing in the sale of premium internet domain names. The primary offering involves facilitating transactions for high-value domain names, allowing businesses and individuals to acquire unique digital assets that can enhance their online presence. The end users include entrepreneurs, startups, and established companies seeking to improve brand visibility and credibility through strategic domain name choices. Pronota.com targets customers globally, with a focus on markets in North America, Europe, and parts of Asia, where demand for premium domain names is particularly strong.Revenue generation for Pronota.com primarily occurs through the sale of domain names, which may be transacted directly with end users or through partnerships with digital marketing agencies and resellers. The transaction structure is typically B2C, where clients purchase individual domain names based on their branding needs. Flagship services include domain name valuation and appraisal, which help clients understand the market potential of their desired domain names. While specific pricing plans for domain acquisitions are proprietary, transactions often reflect the market value of the domains, influenced by factors such as length, keyword relevance, and market demand.Pronota NV plans to leverage its recent funding of EUR 3.7 million secured in January 2012 to enhance its product offerings and expand into new markets. The company aims to develop new services related to domain name appraisal and valuation, targeting an expansion into Asia and Europe by 2023. The involvement of returning investors demonstrates confidence in Pronota's strategy to capitalize on the growing demand for premium domain names.

## Funding rounds

- Series C, Dec 19, 2012, $1.8M — EQT Life Sciences, Gimv, KBC Private Equity, Johnson & Johnson Innovation, MP Healthcare Venture Management, The Institute for the Promotion of Innovation by Science and Technology in Flanders, VIB, MedSciences Capital
- Series B, Jan 12, 2010, $0.3M — MedSciences Capital
- Series B, Nov 12, 2009, $1.9M — MP Healthcare Venture Management
- Series B, Jul 8, 2009, $6.8M — EQT Life Sciences, Gimv, KBC Private Equity, Johnson & Johnson Innovation, Baekeland Fonds, The Institute for the Promotion of Innovation by Science and Technology in Flanders, VIB
- Series A, Aug 22, 2006, $11M — EQT Life Sciences, Gimv, KBC Private Equity, Johnson & Johnson Innovation, Baekeland Fonds
- Series A, Apr 19, 2006, $7.3M — EQT Life Sciences, Johnson & Johnson Innovation

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B, Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B, Series C
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A, Series B, Series C
- KBC Private Equity (https://capitalatlas.ai/funds/kbc-private-equity) — Series A, Series B, Series C
- Baekeland Fonds (https://capitalatlas.ai/funds/baekeland-fonds) — Series A, Series B
- The Institute for the Promotion of Innovation by Science and Technology in Flanders — Series B, Series C
- VIB — Series B, Series C
- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Series B, Series C
- MedSciences Capital (https://capitalatlas.ai/funds/medsciences-capital) — Series B, Series C